Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
Completed · Phase 1/Phase 2
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cell to kill melanoma cells. Combining vaccine therapy with interleukin-12 may kill more melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy plus interleukin-12 in treating patients who have metastatic melanoma.
Key facts
- Study ID
- NCT00002952
- Run by
- University of Chicago
- People needed
- 20
- Starts
- 1997-01-01
- Expected to finish
- 2002-11-01
- Last updated by the study team
- 2013-09-05
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.